Form 4: Progyny CFO Sells Shares Under 10b5-1 Plan

Progyny's Chief Financial Officer, Mark S. Livingston, has sold 8,275 shares of common stock for $25.50 per share, totaling $210,987.50, as part of a pre-arranged trading plan.

Summary

• Mark S. Livingston, Chief Financial Officer of Progyny, Inc., reported a transaction on May 20, 2026.
• He sold 8,275 shares of common stock.
• The sale was executed at a price of $25.50 per share.
• The total value of the transaction was $210,987.50.
• This sale was made pursuant to a Rule 10b5-1 trading plan established on August 15, 2025.
• Following this transaction, Mr. Livingston beneficially owns 79,063 shares of common stock.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a slightly negative sentiment due to the CFO selling shares, even though it was conducted under a pre-arranged plan.

Negatives

• Company insider, the CFO, sold a significant number of shares.

Risks

• The sale of shares by a key executive could be interpreted negatively by the market, potentially impacting investor sentiment.
• While executed under a 10b5-1 plan, the sale represents a reduction in the CFO's direct beneficial ownership.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports a past transaction.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, can sometimes be perceived as a negative signal by the market, regardless of the underlying strategic reasons. Investors often scrutinize such transactions for insights into management's confidence in the company's future prospects.

Stakeholder Impact

• Shareholders: May view the CFO's sale as a potential negative signal, possibly leading to short-term share price pressure.
• Employees: May interpret the sale in various ways, potentially impacting morale depending on broader company performance and communication.
• Management: The sale is a personal financial decision by the CFO, executed under regulatory guidelines.

Key Dates

Recommendation

The filing reports an insider sale under a 10b5-1 plan, which is a routine event for executives. While insider selling can be a negative signal, the pre-arranged nature of the trade mitigates immediate concern. Without further context on the company's performance or the CFO's rationale beyond the plan, a 'hold' recommendation is prudent, suggesting investors monitor future filings and company performance.

Keywords

Progyny, PGNY, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Mark S. Livingston, CFO, Beneficial Ownership